



medicines
patent
pool

VIA REGISTERED POST AND EMAIL

Attention: General Counsel

Remington Pharmaceutical Industries (Pvt.) Ltd.

18-Km Multan Road, Lahore, 53800, Pakistan

Email: legal@remingtonpharma.com; mamjad@remingtonpharma.com

Date: 29 August 2025

Re: Mutual Termination Letter of Agreement to Terminate Molnupiravir Licence Agreement

Dear General Counsel,

We refer to the licence agreement between the Medicines Patent Pool ("MPP") and Remington Pharmaceutical Industries (Pvt.) Ltd. Limited ("Licensee") dated 1/5/2022 concerning patents and know-how pertaining to molnupiravir ("Licence Agreement").

MPP and Licensee agree that the Licence Agreement is hereby terminated as of the date of last signature below. This termination is without prejudice to the surviving provisions of the Licence Agreement, including sections 3A, 6.1(e), 7.3, 8, 10.5, 11, and 12.

Please acknowledge your agreement to this termination letter by signing and returning a copy to us.

Sincerely,

For and on behalf of **Medicines
Patent Pool**

Name: Chan Park
Title: General Counsel
Date: 29 August 2025

For and on behalf of Remington
Pharmaceutical Industries
(Pvt.)Ltd

Name: Muhammad Younas
Title: Company Secretary
Date: 23-09-2025